Anixa Biosciences, Inc., a Biotechnology company focused on treatment and prevention of cancer and Infectious Diseases , announced the results of a genomic variant analysis done with its partner, MolGenie, GmbH,non potential compounds to treat COVID-19. The data indicate that the ncompounds in development should be effective against the Omicron variantnof SARS-CoV-2, in addition to the previously identified Delta variant nof the virus.
SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the results of a genomic variant analysis done with its partner, MolGenie, GmbH, on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant of SARS-CoV-2, in addition to the previously identified Delta variant of the virus.